Most claims about Alpha Lipoic Acid travel faster than the evidence behind them. So when a meta-analysis lands, it's worth reading slowly

Nutrients, 2023: ten randomized controlled trials, 1,242 patients, oral ALA versus placebo in diabetic polyneuropathy — doses from 600 to 1,800 mg/day

What the authors found:
·Sensory symptoms improved. Total symptom scores came down, with a dose-related trend
·Global satisfaction scores favored ALA over placebo.
·Nerve conduction and vibration perception thresholds did not move.

That last line is the useful one. The evidence supports symptom relief, not nerve repair - and formulators who know the difference write better labels and make better promises

Full paper (open access): Nutrients 2023, 15, 3634
DOI: 10.3390/nu15163634

At Longzen, Alpha Lipoic Acid is our core nutraceutical line - APIs and coated granules, supplied to supplement manufacturers worldwide.